Tobin Schilke - Dec 31, 2022 Form 4 Insider Report for Revance Therapeutics, Inc. (RVNC)

Role
CFO
Signature
/s/ Dwight Moxie, Attorney-in-Fact
Stock symbol
RVNC
Transactions as of
Dec 31, 2022
Transactions value $
$7,856
Form type
4
Date filed
1/3/2023, 03:29 PM
Previous filing
Dec 16, 2022
Next filing
Jan 10, 2023

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction RVNC Common Stock Award $7.86K +645 +1.04% $12.18 62.6K Dec 31, 2022 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 These shares were acquired by Mr. Schilke under the Issuer's 2014 Employee Stock Purchase Plan on December 31, 2022 in a transaction that was exempt under both Rule 16b-3(d) and Rule 16b-3(c).